Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Bestvina on Challenges With Interpreting Molecular Reports in Lung Cancer

December 6th 2021

Christine Bestvina, MD, discusses challenges with interpreting molecular reports in lung cancer.

FDA Approval Sought for Poziotinib in HER2 Exon 20–Mutated NSCLC

December 6th 2021

A new drug application seeking the approval of poziotinib as a potential therapeutic option for patients with previously treated locally advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations has been submitted to the FDA.

Updates From CheckMate 9LA and POSEIDON Studies in Advanced NSCLC

December 3rd 2021

Heather Wakelee, MD, shares updates from the CheckMate 9LA study, and Vamsidhar Velcheti, MD, reviews key data from the phase 3 POSEIDON study for patients with NSCLC.

Chemoimmunotherapy in Advanced NSCLC Treatment

December 3rd 2021

Experts in lung cancer discuss recent updates from ESMO 2021 and IASLC 2021 WCLC on combination immunotherapy plus chemotherapy for the treatment of advanced NSCLC.

Dr. Leal on the Evolution of Treatment in EGFR Exon 20 Insertion+ NSCLC

December 2nd 2021

Ticiana Leal, MD, discusses the evolution of treatment in EGFR exon 20 insertion–positive non–small cell lung cancer.

Atezolizumab Provides Option for Patients With NSCLC at High Risk of Recurrence

December 2nd 2021

Nasser Khaled Altorki, MD, provides insight on the results of the IMpower010 trial as well as post hoc analyses from the trial and what they signal for the remainder of this patient population.

Dr. Garon on the Potential Clinical Implications of the TROPION-Lung01 Trial in NSCLC

December 1st 2021

Edward B. Garon, MD, discusses the potential impact of the ongoing, phase 3 TROPION-LUNG01 trial in non–small cell lung cancer.

FDA Issues Complete Response Letter to Plinabulin for Chemo-Induced Neutropenia

December 1st 2021

The FDA has issued a complete response letter to the new drug application seeking the approval of plinabulin in combination with granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

Academic Perspectives in Non-Small Cell Lung Cancer

December 1st 2021

In this clinical case review, academic experts share insights into the disease management of patients with NSCLC, discuss factors impacting treatment selection and sequencing strategies, and evaluate the evolving landscape of immunotherapy-based regimens.

Dr. Bordoni on the Utility of Adjuvant Atezolizumab in the Adjuvant Setting in NSCLC

November 30th 2021

Rodolfo Bordoni, MD, discusses the utility of ​atezolizumab in the adjuvant setting in non–small cell lung cancer.

Experts Review Key Data From ESMO Congress 2021

November 29th 2021

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion Mutations

November 25th 2021

Before closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.

Dr. Leal on Developments Made in EGFR Exon 20–Mutant NSCLC Treatment

November 24th 2021

Ticiana Leal, MD, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer.

Treatment of Advanced NSCLC With Dual Immune Checkpoint Inhibitors: 4-Year Update of CheckMate 227

November 24th 2021

Sandip P. Patel, MD, reviews updates on dual immunotherapy agents for the treatment of advanced NSCLC including the 4-year update from the CheckMate 227 study.

Treatment of Advanced NSCLC With Immune Checkpoint Inhibitors

November 24th 2021

Drs Vamsidhar Velcheti, Ani Balmanoukian, Heather Wakelee, and Stephen Liu discuss recent updates on single-agent immunotherapy regimens in patients with NSCLC.

Advances in Diagnostics and Therapeutics Propel Interventional Pulmonology Forward

November 23rd 2021

Nathaniel Ivanick, MD, FCCP, discusses the evolution of interventional pulmonology, the benefits of robotic navigational bronchoscopy and other novel technologies in the field, and ongoing research that could further push the paradigm forward.

Sintilimab Combo Reduces Risk of Progression by 54% in EGFR-Mutated Nonsquamous NSCLC

November 22nd 2021

The addition of sintilimab to a bevacizumab biosimilar and pemetrexed/cisplatin resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with EGFR-mutated, nonsquamous non–small cell lung cancer who progressed after an EGFR TKI.

Mobocertinib Provides Treatment Option for EGFR Exon 20–Mutant NSCLC

November 20th 2021

Joel Neal, MD, PhD, discusses the evolving treatment landscape for patients with EGFR exon 20–mutant non–small cell lung cancer.

Third SARS-CoV2 Vaccine Shows Evidence of Seroconversion in Lung Cancer

November 19th 2021

Three doses of the SARS-CoV2 vaccine were shown to be safe and effective in patients with lung cancer, particularly in those with minimal serologic response after receiving only 2 doses.

Dr. Moutafi on the Results of a Study Evaluating Biomarkers of Resistance in NSCLC

November 19th 2021

Myrto Moutafi, MD, MSc, discusses the results of a study evaluating biomarkers of resistance in non–small cell lung cancer.